#Taipei #USA #Bioprocessing #Leadgene Biosolutions #BICO Group

Leadgene Biosolutions: A New Phase of Growth

Leadgene Biosolutions, Inc., previously known as CYTENA BPS, has initiated a transformative rebranding following its separation from the BICO Group. This strategic move isn't merely a name change; it's a comprehensive step towards integrating with Leadgene Biomedical, a formidable player in the biotechnology sector that specializes in the development of recombinant proteins, antibodies, and diagnostic reagents. This consolidation is set to enrich the company’s portfolio, offering a holistic range of bioprocessing products and services tailored for both research and industrial scenarios.

The rebranding symbolizes a distinctive pathway for Leadgene Biosolutions, positioning it to capitalize on the growing global markets for bioprocessing and cell-based research. By combining forces with Leadgene Biomedical, the company is gaining critical expertise that will drive its growth agenda while ensuring high-quality service delivery. With this merger, the focus is not just on expansion but also on elevating their operational capabilities to meet the dynamic needs of the biotech landscape.

A highlight of this integration is the advancement of Leadgene's signature technologies, including the S.NEST®, C.NEST®, and C.BIRD™ microbioreactor systems. These systems are acclaimed for their unrivaled capability to facilitate high-throughput culture processes in both 24- and 96-well formats, complemented by real-time monitoring of critical parameters such as dissolved oxygen (DO), pH levels, oxygen consumption rate (OCR), and extracellular acidification rate (ECAR). The commitment to updating and expanding the application of these technologies will allow the company to support more robust bioprocessing workflows and detailed long-term metabolism assays, solidifying its reputation as a leader in the field.

Cheng-Han (Charles) Tsai, CEO of Leadgene Biosolutions, expressed optimism regarding the rebranding. He stated, “Building on proven strengths in bioprocessing, the integration gives Leadgene Biosolutions the expanded expertise to advance our long-term plans with refined focus.” This confidence is echoed by Dr. Chasel Yung-Chun Chuang, Chairman of Leadgene Biomedical, who emphasizes that the newly amalgamated entity now provides one of the most comprehensive end-to-end bioprocessing ecosystems. As the industry continues to evolve, such transformations will empower clients to expedite their journey from initial research phases to clinical-ready workflows.

In the wake of these developments, Leadgene Biosolutions has reassured its current and prospective clients that all existing agreements, demo schedules, warranties, and support services will remain unaffected during this transition. The company is poised for a gradual reveal of its new brand identity, which will not only unify its image but also resonate with the progressive vision of the group as a whole.

Potential clients and stakeholders can look forward to a more engaging and coherent interaction with Leadgene as they navigate future projects. The company’s websites, Leadgene Biosolutions and Leadgene Biomedical, serve as platforms for accessing more information regarding their extensive offerings and innovations. As Leadgene navigates this critical juncture, it remains committed to pushing the boundaries of bioprocessing and cell-based research, fostering innovation and growth in a rapidly evolving field.